


Risk Awareness Dialogue Aid for Healthcare Professionals to Counsel Patients and Carers on the Potential for Inadvertent Use of an Empty Salbutamol pMDI



The purpose of this material is for HCPs to reinforce the appropriate use of Salbutamol pMDI when counseling patients and carers.

Please convey the key instructions below thoroughly:



Additional Information

How to access the website:



Detailed information on this drug is available on GSKpro AZ | Prescribing Information for Healthcare Professionals.

In accordance with the requirements of the Resolution of the Cabinet of Ministers of the Republic of Azerbaijan "Regulations of the pharmacovigilance of medicinal products" dated 15 December 2019 and Resolution № 39, 25.08.2020 on approval of the "Guidelines for Good Pharmacovigilance Practice" approved by the Azerbaijan Republic Ministry of Health Analytical Expertise Center Pharmacovigilance sector all suspected adverse reactions should be reported to the cioms@pharma.az

How to report adverse reactions:

In addition, regarding the occurrence of adverse reactions after administration of the drug, please report to GlaxoSmithKline Export Limited by e-mail: pm.safety@gsk.com